MARKETS
Markets

Reported Earlier: Sandoz Canada Launches Lower-Cost Generic Version Of Novo Nordisk’s Ozempic, Expanding Access to Semaglutide for Type 2 Diabetes

Sep 18, 2026 · 03:16 PM ET· updated 1h ago

PrSandoz® Semaglutide, a generic version of PrOzempic®, approved for the treatment of adult patients with type 2 diabetesThis lower-cost alternative supports improved affordability and access to type 2 diabetes

Share
Why It Matters

A company called Sandoz made a cheaper copy of a popular diabetes medicine. When cheaper versions exist, the original company might sell less medicine or lower prices.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.